智通财经APP讯，华海药业(600521.SH)公告，公司下属子公司上海华奥泰生物药业股份有限公司(“华奥泰”)就HB0025联合化疗一线治疗晚期/复发子宫内膜癌经过与国家药品监督管理局药品审评中心(“CDE”)Ⅱ期临床试验结束/Ⅲ期临床试验启动前的会议沟通，公司将正式启动HB0025注射液子宫内膜癌的Ⅲ期临床试验。
智通财经APP讯，华海药业(600521.SH)公告，公司下属子公司上海华奥泰生物药业股份有限公司(“华奥泰”)就HB0025联合化疗一线治疗晚期/复发子宫内膜癌经过与国家药品监督管理局药品审评中心(“CDE”)Ⅱ期临床试验结束/Ⅲ期临床试验启动前的会议沟通，公司将正式启动HB0025注射液子宫内膜癌的Ⅲ期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.